VA
INZY

VR Adviser’s Inozyme Pharma INZY Stock Holding History

VR Adviser’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,709,987
Closed -$2.85M – 27
2022
Q4 		$2.85M Hold
2,709,987
– – 0.48% 25
2022
Q3 		$7.26M Hold
2,709,987
– – 1.12% 19
2022
Q2 		$12.9M Buy
+2,709,987
New +$11.8M 2.55% 13

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser's INZY Position: Q1 2023 in Review

VR Adviser sold out of Inozyme Pharma (INZY) in Q1 2023, closing a stake of 2,709,987 shares — an estimated $2.85M sold.

VR Adviser first reported a position in INZY in Q2 2022 and held it in 3 quarters. The position peaked at $12.9M in Q2 2022. 49 funds tracked by Wall St. Rank hold INZY as of Q1 2023.

  • VR Adviser reported no remaining Inozyme Pharma position as of Q1 2023 after selling out during the quarter.
  • VR Adviser sold 2,709,987 Inozyme Pharma shares in Q1 2023, an estimated $2.85M.
  • VR Adviser first reported a position in Inozyme Pharma in Q2 2022 and held it in 3 quarters.
  • VR Adviser's Inozyme Pharma position peaked at $12.9M in Q2 2022.
  • 49 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.